Article

SABCS: Debu Tripathy Discusses PI3 Kinase Inhibitors in Breast Cancer

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving a PI3 kinase inhibitor showed interesting results.

While the clinical trial involving the investigational agent pictilisib with an aromatase inhibitor had only modest results, interest in this type of targeted therapy remains, particularly in different stages of the disease and in combination with other drugs.

You can read more on the study at "Early Phase Study Finds PI3K Inhibitor Pictilisib Helps a Subset of Advanced Breast Cancer Patients."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Related Content